Medical Breakthrough Boom

Tuesday, 17 Jun 2008 | 6:11 PM ET

On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.

Alzheimer’s advance

A new Alzheimer’s drug called bapineuzumab worked in a substantial number of patients in an intermediate clinical trial, supporting a prior decision to start final Phase III tests. If successful in final-stage trials, the medicine could be the world's first drug to modify the course of Alzheimer's rather than just relieving its symptoms.

Some analysts have forecast eventual annual sales of $13 billion, which would make it the biggest drug ever. The drug comes from Elan and Wyeth.

It’s always good to see something like this but it’s a Phase II trial, says Pete Najarian. I’m watching Myriad Genetic for their Alzheimer’s drug that’s in Phase III trials.

Parkinsons drug

A new drug from Teva Pharmaceutical showed promising results as a Parkinson's treatment. 1 mg tablets of the drug Azilect slowed the progression of the neurological disorder in a Phase III trial. According to Gal Reiter, an analyst at Israeli brokerage Clal Finance, Azilect could become the leading drug in the treatment of Parkinsons in only a few years.

I think it’s great news for Teva and great news for all of us, says Najarian.

Vision treatment

Allergan received Food and Drug Administration approval for an injectable eye drug to treat retinal diseases. Trivaris, which is injected directly into the eye, is a steroid that reduces inflammation of the retina that can lead to vision loss.

Tomorrow's Trades #2
Discussing the meical breakthrough boom, with the Fast Money team.

I think this is huge, Najarian says.

Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to fastmoney@cnbc.com.

Trader disclosure: On June 17, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Adami Owns (AGU), (C), (BTU), (NUE), (GS), (INTC), (MSFT); Macke Owns (INTC), (MSFT), (ATVI), (WMT); Najarian Owns (AAPL), (BHI), (CHK), (TSO), (XLF), (MYGN),(ENER); Najarian Owns (MS) Puts, (BAC) Puts; Terranova Owns (LUV), (FXC); Terranova Is Long Dec 2008 Crude Oil; Terranova Is Short Dec 2009 Crude Oil

Terranova is chief alternatives strategist at Phoenix Investment Partners; Phoenix Investment Partners Ltd. Owns (RWX), (DBC), (DBV), (IGE), (AAI), (ALK), (AMR,) (APA), BP plc, British Airways plc, (CHK), (CVX), (COP), (CAL), (DAL), ENI SPA, (XOM), Gazprom, (HA), (HES), (HOC), (HSE), (JBLU), Lukoil, (MRO), (MUR), (OXY), Petrobras Intl Fin, Petro-Canada, (PBR), Petroleos De Venezuela, (QAN), (RJET), Royal Dutch Shell plc A Shares, (SKYW), (LUV,) (SU), (TSO), Texaco Capital, Total SA, (UAUA), (LCC), (VLO)

  Price   Change %Change


Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET
  • Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

  • Scott Wapner is host of the "Fast Money Halftime Report," which airs weekdays from 12 p.m. to 1 p.m. ET.

  • Guy Adami is a contributor on CNBC's "Fast Money." He also is managing director of stockMONSTER.com.

  • Najarian, the "Pit Boss," is cofounder of optionMONSTER.com, a news site for options traders.

  • Finerman is president of Metropolitan Capital Advisors, Inc., a company she co-founded.

  • Founder of EmergingMoney.com

  • Chief Market Strategist for Virtus Investment Partners & CNBC Contributor

Halftime Report